MedTrace Logo

Evaluation the Safety of hemay005 Tablets

NCT06908642 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 468

Last updated 2025-12-09

No results posted yet for this study

Summary

Explore the influence of different administration methods (titration/non-titration) of Hemay005 tablets on the incidence of adverse reactions.

Conditions

Interventions

DRUG

Hemay005 tablet

Hemay005 is a small molecule PDE4 inhibitor.

DRUG

Placebo

Placebos are the same as drugs, but contain no Hemay005.

Sponsors & Collaborators

  • Anhui Hemay Pharmaceutical Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-12-25
Primary Completion
2025-06-03
Completion
2025-06-03

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06908642 on ClinicalTrials.gov